1
|
Saunders L, Kadhel P, Costet N, Rouget F, Monfort C, Thomé JP, Guldner L, Cordier S, Multigner L. Hypertensive disorders of pregnancy and gestational diabetes mellitus among French Caribbean women chronically exposed to chlordecone. ENVIRONMENT INTERNATIONAL 2014; 68:171-6. [PMID: 24727072 DOI: 10.1016/j.envint.2014.03.024] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Revised: 03/20/2014] [Accepted: 03/20/2014] [Indexed: 05/15/2023]
Abstract
Few studies have explored the consequences of environmental exposure to organochlorine pesticides for gestational hypertension (GH), preeclampsia (PE) and gestational diabetes mellitus (GDM). Chlordecone is a persistent organochlorine pesticide that was used intensively, and almost exclusively, in the French West Indies until 1993. We investigated the impact of prenatal exposure to chlordecone on the occurrence of GDM, GH and PE by studying 779 pregnant women enrolled in a prospective mother-child cohort (Timoun Study) in Guadeloupe between 2004 and 2007. Chlordecone exposure was determined by assaying maternal plasma and information about pregnancy complications was obtained from midwives, pediatricians and hospital medical records after delivery. The risks of GH (n=65), PE (n=31) and GDM (n=71) were estimated by multiple logistic regression including potential confounders. Levels of chlordecone plasma concentration in the third (OR=0.2; 95% confidence interval (CI): 0.1, 0.5) and fourth quartiles (OR=0.3; 95% CI: 0.2, 0.7) were associated with a statistically significant decrease in the risk of GH. A log10 increase in chlordecone concentration was significantly associated with lower risk of GH (OR=0.4; 95% CI: 0.2, 0.6). No significant associations were observed between the chlordecone exposure and the risk of PE or GDM. This study suggests an inverse association between chlordecone exposure during pregnancy and GH. Further studies are required to determine the underlying mechanism, or the potential unknown confounding factors, resulting in this association.
Collapse
Affiliation(s)
- Lauren Saunders
- Team of Epidemiological Research on Environment, Reproduction and Development, National Institute for Health and Medical Research (INSERM UMR1085, IRSET), Rennes, France
| | - Philippe Kadhel
- Team of Epidemiological Research on Environment, Reproduction and Development, National Institute for Health and Medical Research (INSERM UMR1085, IRSET), Rennes, France; Gynecology and Obstetric Unit, CHU Pointe à Pitre/Abymes, Guadeloupe, French West Indies, France
| | - Nathalie Costet
- Team of Epidemiological Research on Environment, Reproduction and Development, National Institute for Health and Medical Research (INSERM UMR1085, IRSET), Rennes, France
| | - Florence Rouget
- Team of Epidemiological Research on Environment, Reproduction and Development, National Institute for Health and Medical Research (INSERM UMR1085, IRSET), Rennes, France
| | - Christine Monfort
- Team of Epidemiological Research on Environment, Reproduction and Development, National Institute for Health and Medical Research (INSERM UMR1085, IRSET), Rennes, France
| | - Jean-Pierre Thomé
- Center for Analytical Research and Technology, Liege University, Belgium
| | - Laurence Guldner
- French Institute for Public Health Surveillance (InVS), Department of Environmental Health, St-Maurice, France
| | - Sylvaine Cordier
- Team of Epidemiological Research on Environment, Reproduction and Development, National Institute for Health and Medical Research (INSERM UMR1085, IRSET), Rennes, France
| | - Luc Multigner
- Team of Epidemiological Research on Environment, Reproduction and Development, National Institute for Health and Medical Research (INSERM UMR1085, IRSET), Rennes, France.
| |
Collapse
|
2
|
Faroon O, Kueberuwa S, Smith L, DeRosa C. ATSDR evaluation of health effects of chemicals. II. Mirex and chlordecone: health effects, toxicokinetics, human exposure, and environmental fate. Toxicol Ind Health 1995; 11:1-203. [PMID: 8723616 DOI: 10.1177/074823379501100601] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
This document provides public health officials, physicians, toxicologists, and other interested individuals and groups with an overall perspective of the toxicology of mirex and chlordecone. It contains descriptions and evaluations of toxicological studies and epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. Additional substances will be profiled in a series of manuscripts to follow.
Collapse
Affiliation(s)
- O Faroon
- Agency for Toxic Substances and Disease Registry, U.S. Department of Health and Human Services, Atlanta, Georgia 30333, USA
| | | | | | | |
Collapse
|
3
|
Ruiz de Elvira MC, Coen CW. Centrally administered neuropeptide Y enhances the hypothermia induced by peripheral administration of adrenoceptor antagonists. Peptides 1990; 11:963-7. [PMID: 1980942 DOI: 10.1016/0196-9781(90)90017-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The distribution of neuropeptide Y in the brain includes extensive coexistence within adrenaline- and noradrenaline-containing neurons and many of its actions are often associated with adrenergic systems. Since neuropeptide Y immunoreactivity is particularly intense in the preoptic area, one of the principal sites for thermoregulation, we have tested the effects of neuropeptide Y on core temperature in normothermic rats, and rats rendered hypothermic by systemic treatment with adrenergic antagonists. In the normothermic rat, intracerebroventricular administration of 1 microgram of neuropeptide Y did not have a significant effect on core temperature. Intraperitoneal treatment with the alpha 1-adrenoceptor antagonist, prazosin, or the beta-adrenoceptor antagonist, propranolol, caused an immediate and significant hypothermia; the intracerebroventricular administration of 1 microgram of neuropeptide Y, 10 minutes after these drugs, strongly potentiated their hypothermic effect. Although intraperitoneal treatment with the alpha 2-adrenoceptor antagonist, idazoxan, had no hypothermic effect per se, the intracerebroventricular administration of NPY 10 minutes after this antagonist led to a significant decrease in core temperature.
Collapse
|